Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-20
    E.g., 2018-09-20

Archive Search

2 results
12:18 PM, Apr 10, 2017  |  BC Extra | Clinical News

Roche's Alecensa tops Xalkori in confirmatory NSCLC trial

Roche (SIX:ROG; OTCQX:RHHBY) said Alecensa alectinib significantly improved progression-free survival (PFS) vs. Xalkori crizotinib, meeting the …
to present full data from the 303-patient study at an upcoming medical meeting. Last week, Alecensa
improving PFS in the Phase III ALUR trial to treat ALK-positive NSCLC. The study compared Alecensa
2:28 PM, Apr 03, 2017  |  BC Extra | Clinical News

Roche's Alecensa passes Phase III NSCLC test

Roche (SIX:ROG; OTCQX:RHHBY) said Alecensa alectinib met the primary endpoint in the Phase III ALUR trial …
to treat anaplastic lymphoma kinase-positive non-small cell lung cancer. Alecensa significantly improved progression-free survival (PFS) vs …
of both platinum-based chemotherapy and Xalkori crizotinib. The open-label study compared twice-daily 600 mg oral Alecensa